Navigation Links
Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)

LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).  The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010.  The grants will be used to advance the clinical development of Inspiration's lead product candidates, IB1001 and OBI-1.  Inspiration is developing IB1001, an intravenous human recombinant factor IX product, for the acute and preventative treatment of bleeding in individuals with hemophilia B.  OBI-1 is Inspiration's intravenous recombinant porcine factor VIII product for the treatment of individuals who have developed inhibitors against human factor VIII and for individuals with acquired hemophilia A.  Inspiration in-licensed OBI-1 from Ipsen SA earlier this year.

Michael Griffith, Ph.D., President and CEO of Inspiration, commented, "We are very pleased to receive these federal grants.  The QTDP grant will further enable Inspiration to continue the development of IB1001 and OBI-1, and address the significant unmet needs of individuals with hemophilia."

Under the QTDP program, tax credits or grants were made available to companies with 250 or less employees to encourage therapeutic discovery projects that showed a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions; reduce the long-term growth of health care costs in the United States; or significantly advance the goal of curing cancer within 30 years.  For additional information on the QTDP program, please visit

About Hemophilia and Acquired Hemophilia

Hemophilia is a bleeding disorder caused by low levels or absence of a protein called a coagulation factor, essential for blood clotting.  The two most common forms of hemophilia are types A and B.  Hemophilia A is caused by a factor VIII deficiency and occurs in ~1 out of every 5,000 male births.  Hemophilia B is caused by factor IX deficiency and occurs in ~1 out of every 30,000 male births.  Approximately 60% of persons with hemophilia have a severe condition, which results in frequent spontaneous bleeding episodes, in addition to serious bleeding after injuries. The annual market for hemophilia treatments is $7.5 billion worldwide.

Acquired hemophilia is a rare though potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) against coagulation factors.  Unlike congenital hemophilia, acquired hemophilia is typically a disorder of middle age and occurs equally in both males and females.  Also, the pattern of bleeding seen in acquired hemophilia is different from that observed in the more common congenital form.  In acquired hemophilia, individuals typically bleed into the skin and soft tissues, as opposed to bleeding into joints, which is more typical in congenital hemophilia.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and to improve the treatment of individuals with inhibitor complications.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two late-stage products in clinical development and two pre-clinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) for the acute and preventative treatment of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A.  IB1001 is currently in Phase 3 clinical development, and OBI-1 is expected to begin the first of two pivotal trials later this year.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors and individuals with factor VII deficiency, and human recombinant FVIII to treat individuals with hemophilia A.

Inspiration has extensive expertise and experience in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization.  The Company's senior leadership was directly responsible for the development and commercialization of the majority of hemophilia products currently on the market.  In addition, in January 2010, Inspiration entered into a strategic partnership with Ipsen SA, leveraging the combined expertise and resources of the two companies.  For further information on Inspiration, please visit

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):